ABSTRACT:
One of the most severe diseases in the world worldwide is prostate cancer in humans. Natural compounds have demonstrated possible anti-cancer properties. One of the potentially therapeutic natural polyphenolic chemicals is rutin. Extracellular vesicles—particularly exosomes—have garnered attention lately due to their potential therapeutic benefits for a variety of chronic illnesses. Exosomes have a variety of functions, such as the ability to stop the growth of cancer cells and trigger apoptosis. In the current in vitro study, the anticancer effect of rutin and exosomes generated from cord blood stem cells (CBSC) on prostate cancer (PC3 and DU145) cells was investigated. The efficacy of rutin and exosome against oxidative stress was assessed using the Comet test, and the expression levels of specific genes, including P53, P21, Caspase3, S100, and BCL2, were evaluated by QPCR. When PC3 and DU145 were exposed to rutin and exosome, there was an apparent increase in DNA damage as compared to the untreated cells. Certain genes showed an increase in expression following both rutin and exosome therapyIt is proposed that the administration of both rutin and exosomes together will cause p53-mediated cell cycle arrest. The combination of rutin and exosome may be able to cause apoptosis more frequently, according to data from both kinds of rutin, exosome, and the combination of both therapies.
Cite this article:
Maysa Alhawamdeh. Synergetic Impact of Combined rutin and Exosme on Apoptosis in Prostate Cancer Cells. Research Journal of Pharmacy and Technology. 2025;18(3):1324-9. doi: 10.52711/0974-360X.2025.00192
Cite(Electronic):
Maysa Alhawamdeh. Synergetic Impact of Combined rutin and Exosme on Apoptosis in Prostate Cancer Cells. Research Journal of Pharmacy and Technology. 2025;18(3):1324-9. doi: 10.52711/0974-360X.2025.00192 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-3-53
REFERENCES:
1. Gandaglia G, Leni R, Bray F, et al. Epidemiology and prevention of Prostate Cancer. 2021; 4(6): 877-892. https://doi.org/10.1016/j.euo.2021.09.006
2. Alenezi BT, Alsubhi MH, Jin X, et al. Global development on causes, epidemiology, aetiology, and risk factors of prostate cancer: An Advanced Study. 2021; 17: 94-117. DOI: 10.9734/bpi/hmms/v17/11228D
3. Nargatti P, Patil S, Patil S, et al. Chemopreventive potential of adrenergic blocker in behavioral stress accelerated prostate cancer development in rats. 2021; 14(2): 787-792. DOI: 10.5958/0974-360X.2021.00137.2
4. Sekhoacha M, Riet K, Motloung P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. 2022; 27(17): 5730. https://doi.org/10.3390/molecules27175730
5. Rawla PJWjoo. Epidemiology of prostate cancer. 2019; 10(2): 63.
6. Boyd K, Kyle JAJUP. An Overview of Prostate Cancer. 2023; 48(7): 40-45.
7. David MK, Leslie SW. Prostate specific antigen. 2020.
8. Karunasinghe N, Minas TZ, Bao B-Y, et al. Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions. 2022; 12(1): 55. https://doi.org/10.1038/s41598-021-04116-8
9. Duffy MJJCC, Medicine L. Biomarkers for prostate cancer: prostate-specific antigen and beyond. 2020; 58(3): 326-339. https://doi.org/10.1515/cclm-2019-0693
10. Lowder D, Rizwan K, McColl C, et al. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. 2022; 531: 71-82. https://doi.org/10.1016/j.canlet.2022.01.028
11. Kruslin B, Škara L, Vodopić T, et al. Genetics of prostate carcinoma. 2021. https://doi.org/10.5644/ama2006-124.327
12. Vickman RE, Franco OE, Moline DC, et al. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. 2020; 7(3): 191-202. https://doi.org/10.1016/j.ajur.2019.10.003
13. Couñago F, Lopez-Campos F, Díaz-Gavela AA, et al. Clinical applications of molecular biomarkers in prostate cancer. 2020; 12(6): 1550. https://doi.org/10.3390/cancers12061550
14. Wang K, Tepper JEJCacjfc. Radiation therapy‐associated toxicity: Etiology, management, and prevention. 2021; 71(5): 437-454. https://doi.org/10.3322/caac.21689
15. Nestor MS, Ablon G, Gade A, et al. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. 2021;2 0(12): 3759-3781. https://doi.org/10.1111/jocd.14537
16. Semwal R, Joshi SK, Semwal RB, et al. Health benefits and limitations of rutin-A natural flavonoid with high nutraceutical value. 2021; 46: 119-128. https://doi.org/10.1016/j.phytol.2021.10.006
17. Deepika, Maurya PKJM. Health benefits of quercetin in age-related diseases. 2022; 27(8): 2498. https://doi.org/10.3390/molecules27082498
18. Asaad JI, Al-Mamoori AM, Shukri HM, et al. The Biochemical Response of Acetyl Cholinesterasein Prostate Cancer in relation to the Environment. 2018; 11(9): 3897-3899.
19. Parsaei M, Akhbari KJNfBHa. Rutin-based phytomedicines for cancer benefit. 2020:71-126.
20. Mezher MN, Auda AAHJRJoP, Technology. Relationship of human papilloma virus (HPV) and epstein barr virus (EBV) with prostate cancer in AL-Najaf Governorate. 2017; 10(10): 3283-3288.
21. Palazzolo S, Memeo L, Hadla M, et al. Cancer extracellular vesicles: next-generation diagnostic and drug delivery nanotools. 2020; 12(11): 3165. https://doi.org/10.3390/cancers12113165
22. Di Bella MAJB. Overview and update on extracellular vesicles: considerations on exosomes and their application in modern medicine. 2022; 11(6): 804. https://doi.org/10.3390/biology11060804
23. Chan M-H, Chang Z-X, Huang C-YF, et al. Integrated therapy platform of exosomal system: hybrid inorganic/organic nanoparticles with exosomes for cancer treatment. 2022; 7(4): 352-367. DOI: 10.1039/D1NH00637A
24. Annapurna MM, Venkatesh B, Chaitanya SMJRJoP, et al. Determination of Cabazitaxel (An Anti-prostate cancer agent) by reverse phase liquid chromatography. 2017; 10(4): 1138-1144.
25. Anderson D, Dobrzyńska MM, Basaran NJT, carcinogenesis,, et al. Effect of various genotoxins and reproductive toxins in human lymphocytes and sperm in the Comet assay. 1997; 17(1): 29-43. https://doi.org/10.1002/(SICI)1520-6866(1997)17:1<29::AID-TCM5>3.0.CO;2-H
26. Alhawamdeh M, Isreb M, Aziz A, et al. Interferon-γ liposome: a new system to improve drug delivery in the treatment of lung cancer. 2021;7(3).
27. Alhawamdeh M, Almajali B, Hourani W, et al. Effect of IFN‑γ encapsulated liposomes on major signal transduction pathways in the lymphocytes of patients with lung cancer. 2024; 27(1): 1-8. https://doi.org/10.3892/ol.2023.14141
28. Gidde ND, Raut ID, Nitalikar MM, et al. Pharmacosomes as drug delivery system: An overview. 2021; 11(2): 122-127.
29. Guo L, Gu J, Hou S, et al. Long non-coding RNA DANCR promotes the progression of non-small-cell lung cancer by inhibiting p21 expression. OncoTargets and therapy. 2018: 135-146.
30. Lombardo D, Kiselev MAJP. Methods of liposomes preparation: Formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. 2022; 14(3): 543. https://doi.org/10.3390/pharmaceutics14030543
31. Raj S R, DN D, Mondal S, et al. Expression analysis of pro-apoptotic BAX and anti-apoptotic BCL-2 genes in relation to lactation performance in Deoni and Holstein Friesian crossbred cows. 2023; 34(4): 1354-1361. https://doi.org/10.1080/10495398.2021.2025066
32. Leclerc E, Heizmann CW, Vetter SJGp, et al. RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. 2009; 28(Specia): 65-75. https://doi.org/10.5167/uzh-26499
33. Alyami BA, Zaki M, Youns M, et al. Rutin Inhibits Hepatic and Pancreatic Cancer Cell Proliferation by Inhibiting CYP3A4 and GST. 2023; 57(2): 1-8.
34. Gao Y, Wang R, Huang T, et al. Synthesis and characterization of rutin-loaded micelles for glioblastoma multiforme treatment: A computational and experimental study. 2023; 86: 104675. https://doi.org/10.1016/j.jddst.2023.104675
35. Motghare AP, Katolkar PP, Lichade TSJRJoP, et al. In-silico prediction of phytoconstituents from Phyllanthus niruri for anticancer activity against prostate cancer targeting MRCK kinases. 2023; 16(9): 4105-4111.
36. Patwardhan MV, Mahendran RJIJoMS. The bladder tumor microenvironment components that modulate the tumor and impact therapy. 2023; 24(15): 12311. https://doi.org/10.3390/ijms241512311
37. Gupta AK, Jain SKJRJoP, Technology. Design of amide bioisosteres of flutamide as novel androgen receptor antagonist in prostate cancer therapy. 2022;15(10): 4667-4676. DOI: 10.52711/0974-360X.2022.00783
38. Lin JP, Yang JS, Lin JJ, et al. Rutin inhibits human leukemia tumor growth in a murine xenograft model in vivo. 2012; 27(8): 480-484. https://doi.org/10.1002/tox.20662
39. Kulchenko N, Kostin A, Chibisov S, et al. Modern principles of early diagnosis of prostate cancer. 2017; 10(3): 696-698. DOI: 10.5958/0974-360X.2017.00130.5
40. Yong DO, Saker SR, Chellappan DK, et al. Molecular and immunological mechanisms underlying the various pharmacological properties of the potent bioflavonoid, rutin. 2020; 20(10): 1590-1596. https://doi.org/10.2174/1871530320666200503053846
41. Rao SV, Kumar SSJRJoP, Technology. Flutamide loaded polymeric nanoparticles for prostate cancer: a review. 2021; 14(8): 4501-4503. DOI : 10.52711/0974-360X.2021.00782
42. Di Cristofano FR, Fong MW, Huntington KE, et al. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis. 2023; 13(1): 307.
43. Nair A, Naik PJRJoP, Technology. Rutin imparts attenuation of Methyl Parathion-Induced base-pair substitution. 2020; 13(12): 5680-5684. DOI: 10.5958/0974-360X.2020.00989.0
44. Kalita B, Das MK, Sharma AKJRJop, et al. Novel phytosome formulations in making herbal extracts more effective. 2013; 6(11): 1295-1301.
45. Chaudhary P, Patel HUJRJoP, Technology. RP-HPLC and Spectrophotometric determination of rutin Trihydrate, Berberine chloride and trigonelline Hydrochloride in Antidiabetic Polyherbal Formulations. 2020; 13(7): 3293-3299.
46. Patidar P, Singh S, Dubey D, et al. Estimation of Rutin in Tephrosia purpurea by HPTLC Method. 2013; 6(1): 58-60.